Open Targets is an innovative, large-scale, multi-year, public-private partnership that uses human genetics and genomics data for systematic drug target identification and prioritisation. In addition to providing the Open Source tools we support, the partnership generates experimental data that helps target discovery. The members of the partnership are Bristol-Myers Squibb (BMS), the European Bioinformatics Institute (EMBL-EBI), GlaxoSmithKline (GSK), Pfizer, Sanofi, and Wellcome Sanger Institute.